Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06992258 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
A Phase 2 study of Colorectal Cancer, sponsored by Criterium.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 9
- Study locations
NCT06992258 is a Phase 2 study of Colorectal Cancer that is actively recruiting participants, run by Criterium. The registered enrollment target is 120 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (92% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT06992258, a Phase 2 study of Colorectal Cancer, is actively recruiting participants, sponsored by Criterium.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 9
- Study locations
Study Summary
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer
Conditions Studied
Interventions
- DRUG Fruquintinib
- DRUG Fruquintinib+ Lonsurf (trifluridine and tipiracil)
Study Locations (9)
Florida
- Mount Sinai Cancer Research Program - Miami Beach
- Orlando Health Cancer Institute - Orlando
Connecticut
- Yale University - New Haven
New Jersey
- Rutgers Cancer Institute - New Brunswick
New York
- NYU Langone Health - New York
Pennsylvania
- UPenn Lancaster-Ann B. Barshinger Cancer Institute - Lancaster
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Mays Cancer Center at University of Texas Health at San Antonio - San Antonio
Virginia
- Inova Schar Cancer - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-10-27 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06992258
The ClinicalTrials.gov registry entry for NCT06992258 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Criterium, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fruquintinib is the first listed.
NCT06992258 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Florida, Connecticut, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06992258 about?
NCT06992258 is a clinical study titled "A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer". A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer
What is the current status of trial NCT06992258?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-10-27. Estimated completion is 2028-12-31.
What conditions does trial NCT06992258 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT06992258?
The interventions under investigation include: Fruquintinib (DRUG), Fruquintinib+ Lonsurf (trifluridine and tipiracil) (DRUG).
Who is sponsoring clinical trial NCT06992258?
This trial is sponsored by Criterium, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06992258 being conducted?
This trial has 9 study locations across Connecticut, Florida, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.